These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 19372901)

  • 1. Antiretroviral therapy-induced liver alterations.
    Walker UA
    Curr Opin HIV AIDS; 2007 Jul; 2(4):293-8. PubMed ID: 19372901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity and liver disease in the context of HIV therapy.
    Vogel M; Rockstroh JK
    Curr Opin HIV AIDS; 2007 Jul; 2(4):306-13. PubMed ID: 19372904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of antiretroviral drug toxicity.
    Feeney E; Muldoon E; Powderly WG
    Curr Opin HIV AIDS; 2006 Sep; 1(5):430-6. PubMed ID: 19372843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of HIV protease inhibitors: clinical considerations.
    Boesecke C; Cooper DA
    Curr Opin HIV AIDS; 2008 Nov; 3(6):653-9. PubMed ID: 19373038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of antiretroviral-induced mitochondrial dysfunction in adipocytes and adipose tissue: in-vitro, animal and human adipose tissue studies.
    Villarroya F; Domingo P; Giralt M
    Curr Opin HIV AIDS; 2007 Jul; 2(4):261-7. PubMed ID: 19372897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiretroviral therapy in coinfected patients: viral hepatitis and tuberculosis.
    Rockstroh JK; Hardy WD
    Curr Opin HIV AIDS; 2006 Sep; 1(5):442-8. PubMed ID: 19372845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of antiretroviral therapy-induced mitochondrial dysfunction.
    Côté HC
    Curr Opin HIV AIDS; 2007 Jul; 2(4):253-60. PubMed ID: 19372896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis virus immune restoration disease of the liver.
    Crane M; Matthews G; Lewin SR
    Curr Opin HIV AIDS; 2008 Jul; 3(4):446-52. PubMed ID: 19373004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipocyte dysfunction in response to antiretroviral therapy: clinical, tissue and in-vitro studies.
    Caron M; Vigouroux C; Bastard JP; Capeau J
    Curr Opin HIV AIDS; 2007 Jul; 2(4):268-73. PubMed ID: 19372898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: perfect control of hepatitis B virus replication and absence of mitochondrial toxicity.
    Tateo M; Roque-Afonso AM; Antonini TM; Medja F; Lombes A; Jardel C; Teicher E; Sebagh M; Roche B; Castaing D; Samuel D; Duclos-Vallee JC
    AIDS; 2009 Jun; 23(9):1069-76. PubMed ID: 19417577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiretroviral therapy-induced lipid alterations: in-vitro, animal and human studies.
    Mallon PW
    Curr Opin HIV AIDS; 2007 Jul; 2(4):282-92. PubMed ID: 19372900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).
    Negredo E; Miró O; Rodríguez-Santiago B; Garrabou G; Estany C; Masabeu A; Force L; Barrufet P; Cucurull J; Domingo P; Alonso-Villaverde C; Bonjoch A; Morén C; Pérez-Alvarez N; Clotet B;
    Clin Infect Dis; 2009 Sep; 49(6):892-900. PubMed ID: 19663689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of HIV protease inhibitors in pregnancy.
    van der Lugt J; Colbers A; Burger D
    Curr Opin HIV AIDS; 2008 Nov; 3(6):620-6. PubMed ID: 19373033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
    Vogel M; Rockstroh JK
    Curr Opin HIV AIDS; 2009 May; 4(3):171-5. PubMed ID: 19532046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atherosclerotic vascular disease in HIV: it is not just antiretroviral therapy that hurts the heart!
    van Leuven SI; Sankatsing RR; Vermeulen JN; Kastelein JJ; Reiss P; Stroes ES
    Curr Opin HIV AIDS; 2007 Jul; 2(4):324-31. PubMed ID: 19372907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?
    Winston A; Khoo S
    Curr Opin HIV AIDS; 2008 Nov; 3(6):608-11. PubMed ID: 19373031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons.
    Dickinson L; Khoo S; Back D
    Curr Opin HIV AIDS; 2008 May; 3(3):296-305. PubMed ID: 19372982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal consequences of HIV and HIV therapy.
    Bagnis CI; Deray G
    Curr Opin HIV AIDS; 2007 Jul; 2(4):314-7. PubMed ID: 19372905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From lipodystrophy and insulin resistance to metabolic syndrome: HIV infection, treatment and aging.
    Capeau J
    Curr Opin HIV AIDS; 2007 Jul; 2(4):247-52. PubMed ID: 19372895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.